Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

Aug 16, 2039formulationUS 11931455
Aug 16, 2039formulationUS 12097284
Aug 16, 2039formulationUS 12097285
Aug 16, 2039formulationUS 12194143
Aug 16, 2039formulationUS 12226526

News(0)

no news has mentioned this drug yet

brand

MYCOPHENOLATE MOFETIL

trade names

Arzip, Cellcept, Myclausen, Mycophenolate mofetil, Mycophenolate mofetil teva, Myfenax

generic

MYCOPHENOLATE MOFETIL

MOA

12.1 Mechanism of Action Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4+ T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Overall, the effect of MPA is cytostatic and reversible.

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 46m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

MYCOPHENOLATE MOFETIL

Marketedupdated 3mo ago

by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 54 investigational indications.

targets

Inosine-5'-monophosphate dehydrogenase (IMPDH)

all catalysts(17)

approval · 17

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE MOFETIL — FDA approval

MYCOPHENOLATE MOFETIL

→

view all 17 catalysts →

Trials studying MYCOPHENOLATE MOFETIL

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 16, 2039

~13.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

Aug 16, 2039formulationUS 11931455
Aug 16, 2039formulationUS 12097284
Aug 16, 2039formulationUS 12097285
Aug 16, 2039formulationUS 12194143
Aug 16, 2039formulationUS 12226526

News(0)

no news has mentioned this drug yet

brand

MYCOPHENOLATE MOFETIL

trade names

Arzip, Cellcept, Myclausen, Mycophenolate mofetil, Mycophenolate mofetil teva, Myfenax

generic

MYCOPHENOLATE MOFETIL

MOA

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 46m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

MYCOPHENOLATE MOFETIL

🐶 often sniffed alongside

targets

all catalysts(17)

Trials studying MYCOPHENOLATE MOFETIL

Patent cliff

patents (5)

News(0)

Report a data issue

comments(0)

MYCOPHENOLATE MOFETIL

🐶 often sniffed alongside

targets

all catalysts(17)

Trials studying MYCOPHENOLATE MOFETIL

Patent cliff

patents (5)

News(0)

Report a data issue

comments(0)